In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2705-2711

  Hutchings, Martin ^a   Kostakoglu, Lale ^b   Zaucha, Jan Maciej ^e   Malkowski, Bogdan ^f   Biggi, Alberto ^g   Danielewicz, Iwona ^e   Loft, Annika ^a   Specht, Lena ^a   Lamonica, Dominick ^d   Czuczman, Myron S ^d   Nanni, Christina ^g   Zinzani, Pier Luigi ^g   Diehl, Louis ^h   Stern, Richard ^b   Coleman, Morton ^c  

^a Rigshospitalet   (Denmark)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f Regional Oncology Centre Bydgoszcz   (Poland)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ACUTE TOXICITY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; SCINTISCANNING; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE; YOUNG ADULT;

EID: 84906805850     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2838     Document Type: Article

References (32)

1. Henry-Amar M, Somers R: Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 17:758-768, 1990
2. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
3. Hutchings M, Loft A, Hansen M, et al: FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
4. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
5. Zinzani PL, Tani M, Fanti S, et al: Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 17:1296-1300, 2006
6. Cerci JJ, Pracchia LF, Linardi CC, et al: 18FFDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51:1337-1343, 2010
7. Hutchings M, Mikhaeel NG, Fields PA, et al: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168, 2005
8. Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J Nucl Med 50:21S-30S, 2009 (suppl 1)
9. Kostakoglu L, Goldsmith SJ, Leonard JP, et al: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107:2678-2687, 2006
10. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
11. Coleman M, Kostakoglu L: Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas. Cancer 107:1425-1428, 2006
12. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
13. Meignan M, Gallamini A, Meignan M, et al: Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257-1260, 2009
14. Barrington SF, Qian W, Somer EJ, et al: Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824-1833, 2010
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
17. Landau S, Everitt BS: A Handbook of Statistical Analyses Using SPSS. Boca Raton, FL, Chapman and Hall/CRC, 2004
18. Collett D: Modelling Survival Data in Medical Research (ed 2). Boca Raton, FL, Chapman and Hall/CRC, 2003
19. HD18 for advanced stages in Hodgkins lymphoma. http://www.clinicaltrials. gov/ct2/show/NCT00515554
20. HD16 for early stage Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/ show/NCT00736320
21. PET scan in planning treatment in patients undergoing combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma (RAPID). http://www.clinicaltrials.gov/ct2/show/NCT00943423
22. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00678327
23. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00433433
24. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801). http://www.clinicaltrials.gov/ct2/show/NCT00784537
25. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL). http://www.clinicaltrials.gov/ct2/show/NCT00795613
26. Radford J, O'Doherty M, Barrington S, et al: Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a "negative" FDGPET scan after 3 cycles ABVD. Blood 112, 2008 (abstr 369)
27. Andre MP, Reman O, Federico M, et al: Interim analysis of the randomized EORTC/LYSA/FIL intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. Blood 120, 2012 (abstr 549)
28. Gallamini A, Rossi A, Patti C, et al: Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses: First interim analysis of the GITIL/FIL HD0607 clinical trial. Blood 120, 2012 (abstr 550)
29. Terasawa T, Lau J, Bardet S, et al: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 27:1906-1914, 2009
30. Hutchings M: How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program 2012:322-327, 2012
31. Biggi A, Gallamini A, Chauvie S, et al: International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 54:683-690, 2013
32. Very early FDG-PET/CT-response adapted therapy for advanced Hodgkin lymphoma (H11). http://www.clinicaltrials.gov/ct2/show/NCT01652261